These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20079523)

  • 1. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.
    Gramling MW; Church FC
    Thromb Res; 2010 May; 125(5):377-81. PubMed ID: 20079523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAI-1, progress in understanding the clinical problem and its aetiology.
    Iwaki T; Urano T; Umemura K
    Br J Haematol; 2012 May; 157(3):291-8. PubMed ID: 22360729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
    Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
    Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?
    Sillen M; Declerck PJ
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
    Stefansson S; McMahon GA; Petitclerc E; Lawrence DA
    Curr Pharm Des; 2003; 9(19):1545-64. PubMed ID: 12871067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
    Lockwood CJ; Krikun G; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis.
    Rabieian R; Boshtam M; Zareei M; Kouhpayeh S; Masoudifar A; Mirzaei H
    J Cell Biochem; 2018 Jan; 119(1):17-27. PubMed ID: 28520219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
    Whitley BR; Beaulieu LM; Carter JC; Church FC
    Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
    Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
    J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.
    Vousden KA; Lundqvist T; Popovic B; Naiman B; Carruthers AM; Newton P; Johnson DJD; Pomowski A; Wilkinson T; Dufner P; de Mendez I; Mallinder PR; Murray C; Strain M; Connor J; Murray LA; Sleeman MA; Lowe DC; Huntington JA; Vaughan TJ
    Sci Rep; 2019 Feb; 9(1):1605. PubMed ID: 30733557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor type-1-deficient mice have an enhanced IFN-gamma response to lipopolysaccharide and staphylococcal enterotoxin B.
    Renckens R; Pater JM; van der Poll T
    J Immunol; 2006 Dec; 177(11):8171-6. PubMed ID: 17114493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 in kidney pathology (Review).
    Małgorzewicz S; Skrzypczak-Jankun E; Jankun J
    Int J Mol Med; 2013 Mar; 31(3):503-10. PubMed ID: 23314920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.
    Webb DJ; Thomas KS; Gonias SL
    J Cell Biol; 2001 Feb; 152(4):741-52. PubMed ID: 11266465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.
    Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M
    J Biol Chem; 2015 Oct; 290(43):25795-804. PubMed ID: 26324706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the plasminogen activator system in the human vascular wall.
    Salame MY; Samani NJ; Masood I; deBono DP
    Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.